A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) (NCT04468984)
TRANSFORM-2
This trial is No longer recruiting
Registration number NCT04468984
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Andrew Perkins
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR